36 studies found for:    " September 29, 2010":" October 29, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
2 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
3 Completed A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
4 Withdrawn Depot Contraception With and Without Lopinavir/Ritonavir
Condition: HIV Infection
Intervention: Drug: DMPA
5 Unknown  Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
Conditions: HIV Infection;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Protease Inhibitor;   Drug: Standard-of-care Antiretroviral therapy
6 Completed Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
7 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
8 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
9 Unknown  Vaginal Innate Immunity in Normal and HIV-Infected Women
Conditions: HIV;   Pregnancy
Intervention: Other: Vaginal lavage specimen
10 Recruiting IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents
Conditions: ADHD;   HIV
Intervention:
11 Active, not recruiting Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
Conditions: HIV;   Hepatitis C;   Liver Fibrosis
Interventions: Drug: Raltegravir;   Drug: Ritonavir-boosted protease inhibitor
12 Completed Young Women's CoOp Study
Conditions: HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions: Behavioral: Young Women's CoOp;   Behavioral: Staying Healthy and Eating Well
13 Recruiting Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections
Condition: HIV
Intervention:
14 Completed Multi-vitamins, HAART and HIV/AIDS in Uganda
Condition: HIV/AIDS
Intervention: Dietary Supplement: Multivitamin supplements B,C and E
15 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
16 Active, not recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
17 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
18 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
19 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
20 Active, not recruiting Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Conditions: HIV Infection;   Bone Loss;   Osteopenia;   Osteoporosis
Intervention: Drug: Zoledronic acid

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years